Aurdan Capital Management LLC Lowers Stake in Abbott Laboratories $ABT

Aurdan Capital Management LLC reduced its holdings in Abbott Laboratories (NYSE:ABT) by 34.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 24,126 shares of the healthcare product maker’s stock after selling 12,938 shares during the period. Abbott Laboratories comprises 1.0% of Aurdan Capital Management LLC’s holdings, making the stock its 25th largest position. Aurdan Capital Management LLC’s holdings in Abbott Laboratories were worth $3,231,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the stock. IMG Wealth Management Inc. increased its position in shares of Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 167 shares in the last quarter. Cloud Capital Management LLC purchased a new stake in shares of Abbott Laboratories during the third quarter worth $29,000. Guerra Advisors Inc acquired a new stake in shares of Abbott Laboratories in the third quarter valued at about $31,000. Anfield Capital Management LLC lifted its stake in shares of Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after buying an additional 104 shares in the last quarter. Finally, Delos Wealth Advisors LLC acquired a new position in Abbott Laboratories during the second quarter worth about $32,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ABT shares. Benchmark initiated coverage on shares of Abbott Laboratories in a research note on Friday, October 10th. They issued a “buy” rating and a $145.00 target price on the stock. Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Piper Sandler cut their target price on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research note on Friday, January 23rd. Wells Fargo & Company boosted their price target on shares of Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a research report on Thursday, October 16th. Finally, Mizuho raised their price objective on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 14th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $137.05.

Abbott Laboratories Price Performance

ABT stock opened at $109.03 on Friday. The business’s fifty day moving average price is $121.22 and its 200 day moving average price is $126.99. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $141.23. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $189.59 billion, a PE ratio of 29.31, a P/E/G ratio of 1.72 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same period in the prior year, the firm earned $1.34 earnings per share. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be paid a $0.63 dividend. The ex-dividend date is Thursday, January 15th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.